I think it should be clear that our vaccine isn't the cure to GBM, at least not for the overwhelming majority. We don't know if, or how many remaining in the living group, now well over 4 years and more, can be called cured, but perhaps there are some. My point is that until you can give it to 100 people, and have all of them cured, you haven't completely cured the disease. Our vaccine is a step in the right direction, and hopefully is a cure for many still alive who wouldn't have been if they hadn't been in the trial.
What won't be known for years, even decades or longer is whether as other things provide benefits for GBM patients whether they will be added to our vaccine, or whether they'll replace it. At this time I believe our company has the right idea, personalized vaccines that help our bodies fight cancer, they very well may be able to adapt the technology to other diseases as well. My point is that years from now we may have made substantial improvements on our current products, or perhaps not, only time will tell. I believe we're constantly building on our capability of making it.
Each day we're one day closer to when we'll know, perhaps we'll get guidance on that by the Annual Meeting a week from tomorrow. All here will certainly be disappointed if we don't. We may not be given a finite date, but I believe the least we should hear is what quarter they will unveil the TLD, and perhaps what technical conference they believe they'll present it at.
We know that ASCO will be a virtual conference this year. I would hope that the threat is sufficiently reduced by the SNO Conference, it can be held in a normal manner, but with some precautions. The key may very well be if we have better treatment, or if a vaccine is available earlier than currently anticipated.
At this point we're just over a week from knowing what will have been discussed. In reality, the SEC wouldn't require a P.R. for such things as announcing an intent to present at SNO, or even when they anticipate filing a BLA. There are many things they can provide guidance about that do not require pre announcing at all, if they are not material events, if essentially they're just anticipation of when certain things will occur, they really need not issue anything before they speak. After the meeting I believe they'll summarize what was presented, and that will be released through the SEC along with the results of the vote at the meeting.
Gary
AI
